 |
 |
| May 28, 2010 |
Proteoderm |
 |
Proteoderm, Inc. a Wholly Owned Subsidiary of Proteonomix, Inc. (PROT) Announces New Product Development |
 |
MOUNTAINSIDE, NJ--(Marketwire - May 28, 2010) - Proteoderm, Inc. a wholly owned subsidiary of Proteonomix, Inc. (PINKSHEETS: PROT) announced today that it has successfully developed a new formulation of Proteoderm. The new formulation will be only available at licensed health professionals' offices. The new product, Proteoderm PS (physician strength) is designed to provide a specific dosage of the active ingredient Matrix NC-138, to the patient depending on the patient's skin type and genomic analysis... |
|
| Read Full Story > |
|
 |
| May 24, 2010 |
Proteoderm |
|
Proteoderm Inc. Accepting
Pre-Orders for Cosmetic Product |
|
MOUNTAINSIDE, NJ-- Proteoderm, Inc. a subsidiary of Proteonomix, Inc. (PINKSHEETS: PROT) opened its retail web site, Proteoderm.com, and began accepting pre-orders for its anti-aging line of skin care products, Proteoderm. Proteoderm was unveiled to the public at the 2008 Session of the 16th Annual Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies. The response to the product was far beyond the Company's initial expectations... |
|
| Read Full Story > |
|
 |
| May 04, 2010 |
StromaCel |
|
StromaCel Technology Licensed for Potential Therapeutic use in the Regrowth of Damaged Cardiac Cells After a Heart Attack |
|
MOUNTAINSIDE, NJ - Proteonomix, Inc. (OTCQB: PROT) (Pinksheets:PROT - News) announces that it has licensed from the Cohen-McNiece Foundation (formed by its President, Michael Cohen, and its Chief Scientific Officer and Vice-President, Ian McNiece, PhD) cellular technology for patients who have suffered myocardial infarctions... |
|
| Read Full Story > |
|
